The phase II portion of the trial enrolls advanced/metastatic NSCLC with EGFR mutation (including T790M) and/or MET amplification progressed or intolerant to standard therapy (NCT05498389). This evidence concerns the gene EGFR and non-small cell lung carcinoma.